Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2022-02-26 Proxy Solicitation & In…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
This is in reference to the notice dated 8th February 2022 ("EGM Notice") convening the Extra-Ordinary General Meeting of the shareholders ("EGM") of Morepen Laboratories Limited (the "Company") ....
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a corrigendum to the Notice of an Extra-Ordinary General Meeting (EGM) scheduled for March 5, 2022. It amends certain details in the original EGM Notice, specifically regarding the conversion price and relevant date for equity shares arising from CCPS conversion. The document references the original EGM Notice and clarifies that all other contents remain unchanged. It also mentions that the corrigendum will be available on the company's and stock exchanges' websites and that an email and public notice will be sent/published. The document is not the EGM Notice itself but an amendment to it, and it is not a report or financial statement. It is an announcement related to a shareholder meeting notice, specifically a correction to the notice of an EGM. Therefore, it fits best under the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings, including amendments to such notices.
2022-02-26 English
Loss of share certificate
Regulatory Filings
2022-02-21 English
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2022-02-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an analyst/investor conference call for Morepen Laboratories Limited regarding their Q3 FY22 financial results. It includes detailed discussions by management about quarterly and nine-month financial performance, business updates, strategic initiatives, and Q&A format typical of earnings calls. The presence of management speakers, detailed financial commentary, and the format of a conference call transcript clearly indicate this is a Call Transcript (CT). The document length (15,000 characters) and content confirm it is the full transcript, not just an announcement or summary.
2022-02-12 English
Please find attached transcript of 'Analyst/ Investor Conference Call' organised on Wednesday, 9th February 2022 at 04:00 P.M. (IST), subsequent to the declaration of unaudited standalone ....
Call Transcript Classification · 95% confidence The document is a transcript of an analyst/investor conference call for Morepen Laboratories Limited regarding their Q3 FY22 financial results. It includes detailed discussions by management about quarterly and nine-month financial performance, business strategy, capital expenditure plans, and operational updates. The presence of a moderator, management speakers, and Q&A format typical of earnings calls is evident. The document explicitly states it is a transcript of the earnings conference call held on February 9, 2022, following the declaration of unaudited financial results for the quarter and nine months ended December 31, 2021. This matches the definition of a Call Transcript (CT) filing type, which is a full text transcript of company conference calls such as earnings calls with Q&A. The document length (15,000 characters) and content confirm it is the transcript itself, not just an announcement or summary. Therefore, the correct classification is CT with high confidence.
2022-02-12 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of an Extra-Ordinary General Meeting (EGM) scheduled for March 5, 2022, including the agenda for the meeting, specifically the variation of rights of preference shares and conversion into compulsorily convertible preference shares. It includes regulatory references to SEBI regulations, Companies Act provisions, and details about voting procedures. The document is not a report of financial results or an audit, nor is it a transcript or presentation. It is a formal notice to shareholders about the EGM and the business to be transacted. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings such as EGMs.
2022-02-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.